 |
Cabiralizumab |
|---|---|
| Trade Name | |
| Orphan Indication | Pigmented villonodular synovitis and tenosynovial giant cell tumor |
| USA Market Approval | USA |
| USA Designation Date | 2016-01-11 00:00:00 |
| Sponsor | Five Prime Therapeutics, Inc.;2 Corporate Drive;South San Francisco, California, 94080 |
